You have 9 free searches left this month | for more free features.

Indolent Lymphoma

Showing 1 - 25 of 4,376

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Indolent Lymphoma, Low-dose Radiotherapy Trial in Beijing (Low-dose radiotherapy)

Recruiting
  • Indolent Lymphoma
  • Low-dose Radiotherapy
  • Low-dose radiotherapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Sep 13, 2022

Inert Non Hodgkin's Lymphoma Trial in Beijing (IBI376, Rituximab)

Recruiting
  • Inert Non Hodgkin's Lymphoma
  • Beijing, China
    Biotherapeutic Department, Chinese PLA General Hospital
Feb 19, 2022

Indolent Lymphoma Trial in Tel Aviv (vegan diet and lifestyle changes)

Recruiting
  • Indolent Lymphoma
  • vegan diet and lifestyle changes
  • Tel Aviv, Israel
    Tel-Aviv Sourasky Medical Center
Jul 5, 2021

Marginal Zone Lymphoma, Follicular Lymphoma, DLBCL Trial in China (Zanubrutinib, Rituximab)

Completed
  • Marginal Zone Lymphoma
  • +2 more
  • Harbin, Heilongjiang, China
  • +3 more
Oct 26, 2021

Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma Trial in United States (dietary supplement, biological,

Active, not recruiting
  • Follicular Lymphoma
  • +3 more
  • Vitamin D
  • +2 more
  • Miami, Florida
  • +6 more
Mar 6, 2022

Follicular Lymphoma, Mantle Cell Lymphoma Trial in New York (Ribavirin)

Terminated
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • New York, New York
    Weill Cornell Medicine
Sep 20, 2021

Lymphoma, B-Cell Trial in Guangzhou (Rituximab Biosimilar, Pegylated Interferon a-2b)

Recruiting
  • Lymphoma, B-Cell
  • Rituximab Biosimilar
  • Pegylated Interferon α-2b
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Apr 6, 2022

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

Completed
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 15, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 20, 2022

CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

Active, not recruiting
  • CD20-positive Non-Hodgkin Lymphoma
  • Rituximab + MG4101
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Feb 4, 2022

Non-Hodgkin's Lymphoma Trial in Japan (bendamustine HCl)

Completed
  • Non-Hodgkin's Lymphoma
  • bendamustine hydrochloride
  • Kanagawa, Japan
  • +3 more
Oct 19, 2020

Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma Trial in Japan (ME-401)

Active, not recruiting
  • Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
  • Nagoya, Aichi, Japan
  • +5 more
Dec 10, 2021

Non Hodgkin's Lymphoma Trial in Sacramento, Santa Rosa (Rituximab, Lenalidomide)

Active, not recruiting
  • Non Hodgkin's Lymphoma
  • Sacramento, California
  • +1 more
Nov 15, 2021

Indolent B-Cell Non-Hodgkin Lymphoma Trial in Worldwide (BI1206)

Recruiting
  • Indolent B-Cell Non-Hodgkin Lymphoma
  • BI1206
  • Atlanta, Georgia
  • +8 more
Mar 1, 2022

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Atlanta (drug, biological,

Recruiting
  • Grade 1 Follicular Lymphoma
  • +7 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Dec 7, 2021

CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)

Recruiting
  • CLL
  • +9 more
  • TG-1801
  • Ublituximab
  • Fayetteville, Arkansas
  • +4 more
Aug 19, 2022

Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent

Completed
  • Ann Arbor Stage III Grade 1 Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 28, 2021

Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma Trial in Duarte, Boston, Portland (Copanlisib, Nivolumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Duarte, California
  • +2 more
Mar 9, 2022

Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma Trial in Australia, United States (NKX019)

Recruiting
  • Lymphoma, Non-Hodgkin
  • +9 more
  • NKX019
  • Denver, Colorado
  • +6 more
Jan 19, 2022

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in Spokane, Salamanca (Zilovertamab vedotin,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +3 more
  • Spokane, Washington
  • +1 more
Aug 12, 2022

Non-Hodgkin Lymphoma Trial in Boston (Blinatumomab)

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • Boston, Massachusetts
    Massachusetts general Hospital
Jan 31, 2021

Follicular Lymphoma, Marginal Zone Lymphoma Trial in Italy, Spain, United States (EO2463, lenalidomide, rituximab)

Recruiting
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • EO2463
  • +2 more
  • Boston, Massachusetts
  • +9 more
Jul 26, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022